These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? Afdhal NH JAMA; 2012 Aug; 308(6):608-16. PubMed ID: 22760235 [TBL] [Abstract][Full Text] [Related]
5. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. Rowe IA Semin Liver Dis; 2020 Nov; 40(4):339-345. PubMed ID: 32906165 [TBL] [Abstract][Full Text] [Related]
6. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ; Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials. Yilmaz Y Curr Drug Targets; 2013 Oct; 14(11):1357-66. PubMed ID: 24020975 [TBL] [Abstract][Full Text] [Related]
8. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis. Shi YW; Fan JG Clin Mol Hepatol; 2023 Feb; 29(Suppl):S228-S243. PubMed ID: 36521452 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Aggarwal P; Noureddin M; Harrison S; Jeannin S; Alkhouri N Expert Opin Investig Drugs; 2022 Feb; 31(2):163-172. PubMed ID: 35060815 [TBL] [Abstract][Full Text] [Related]
11. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Drescher HK; Weiskirchen S; Weiskirchen R Cells; 2019 Aug; 8(8):. PubMed ID: 31394730 [TBL] [Abstract][Full Text] [Related]
13. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Rinella ME; Tacke F; Sanyal AJ; Anstee QM; Hepatology; 2019 Oct; 70(4):1424-1436. PubMed ID: 31287572 [TBL] [Abstract][Full Text] [Related]
14. Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. Williams RN; Filozof C; Goldstein BJ; Cusi K Clin Pharmacol Ther; 2017 Apr; 101(4):444-446. PubMed ID: 28032901 [TBL] [Abstract][Full Text] [Related]